Aaron Siegmund

Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met Kinase

Brian K. Albrecht, Jean-Christophe Harmange, David Bauer et al. · Journal of Medicinal Chemistry · 2008 · 138 citations · Full text

Combinatorial Chemistry, Chemoprevention Strategy, Selective Inhibitors +22

Discovery of a Potent, Selective, and Orally Bioavailable c-Met Inhibitor: 1-(2-Hydroxy-2-methylpropyl)-<i>N</i>-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1<i>H</i>-pyrazole-4-carboxamide (AMG 458)

Longbin Liu, Aaron Siegmund, Ning Xi et al. · Journal of Medicinal Chemistry · 2008 · 94 citations · Full text

Pharmaceutical Science, Metabolic Hot Spot, Chemoprevention Strategy +21

Design, Synthesis, and Biological Evaluation of Potent c-Met Inhibitors

Noel D. D’Angelo, Steven F. Bellon, Shon K. Booker et al. · Journal of Medicinal Chemistry · 2008 · 90 citations · Full text

Molecular Docking, Medicinal Chemistry, Drug Target +13

Structure-Based Design of Novel Class II c-Met Inhibitors: 2. SAR and Kinase Selectivity Profiles of the Pyrazolone Series

Longbin Liu, Mark H. Norman, Matthew Lee et al. · Journal of Medicinal Chemistry · 2012 · 74 citations · Full text

Drug Target, Chemical Biology, Pharmaceutical Chemistry +21

Phospshoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure–Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives

Nobuko Nishimura, Aaron Siegmund, Longbin Liu et al. · Journal of Medicinal Chemistry · 2011 · 59 citations · Full text